Blue Jet Healthcare Q1 FY25 results (Apr–Jun 2024) and concall

Blue Jet Healthcare reported a revenue dip in Q1 FY25, primarily impacted by extended transit times due to the Red Sea situation, which delayed revenue recognition. Despite this, the company maintained strong profitability and continued its strategic capacity expansion, adding 120KL for cardiovascular intermediates and planning further additions for contrast media. Management expressed confidence in its pipeline and future growth, aiming to sustain current margin levels.